Structure-Toxicity Relationships of Amyloid Peptide Oligomers by Patrick Walsh & Simon Sharpe
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Structure-Toxicity Relationships  
of Amyloid Peptide Oligomers 
Patrick Walsh and Simon Sharpe 
The Hospital for Sick Children, and the University of Toronto 
Canada 
1. Introduction 
The accumulation of misfolded proteins as insoluble, fibrillar aggregates is characteristic of 
several degenerative diseases. Examples include the proteins involved in amyloid diseases 
such as Alzheimer’s disease (Aβ) (Glenner and Wong 1984), type II diabetes (amylin) 
(Cooper et al. 1987) and Parkinson’s disease (α-synuclein) (Spillantini et al. 1997), as well as 
the mammalian prion diseases (PrP) (Prusiner 1982). While infectivity and onset differ 
between amyloid and prion diseases, recent evidence suggests that soluble protein 
oligomers, rather than fibrils, are the cytotoxic species in each case (Lambert et al. 1998; 
Bucciantini et al. 2002; Kayed et al. 2003; Walsh and Selkoe 2004; Silveira et al. 2005; Baglioni 
et al. 2006; Simoneau et al. 2007). It has been suggested that these non-fibrillar assemblies 
may be a common element of all amyloid diseases, and non-fibrillar oligomers formed by 
several amyloid proteins have been identified in vivo or produced in vitro. Regardless of 
protein sequence, these oligomers share several key features, including reactivity to 
structural antibodies, the ability to permeabilize model membranes, and cytotoxicity to 
cultured neurons. However, despite their potential importance in the pathogenesis of 
amyloid diseases, the details of the molecular structure of these non-fibrillar oligomers are 
only now beginning to emerge, as is their relationship to mature fibrils, and to the onset of 
disease. 
The mechanism or mechanisms through which these oligomeric species induce cell death 
and contribute to the pathology of amyloid diseases remain a matter of some debate. 
Current hypotheses include a physical disruption of cellular membranes, formation of 
amyloid pores or channels, induction of oxidative stress, or interactions with receptor 
proteins on the cell surface leading to either altered protein function, or the initiation of a 
signaling event. Defining the link between the structure of misfolded protein aggregates and 
the concurrent gain of a toxic functionality is inhibited by the inherent difficulties of 
studying aggregative proteins, and is further complicated by the ability of amyloid proteins 
and peptides to form several distinct types of oligomers and fibrils, which often exist as 
heterogeneous mixtures. Each species of aggregate may exhibit varied biological activity, 
different local structure or gross morphology and typically contains different numbers of 
monomers per assembly. Despite these challenges, there has been significant recent progress 
in obtaining high-resolution structural details of amyloid fibrils and non-fibrillar oligomers, 
and in defining their biological mode of action. In this chapter, we review the current 
knowledge of the structure-toxicity relationship of non-fibrillar amyloid oligomers. 
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2. Amyloid fibrils 
2.1 Overview of amyloid fibril structure 
As the final stage in the assembly pathway for misfolded amyloid proteins, accumulation of 
fibrils has long been seen as the hallmark of amyloid diseases. Since they were the only 
readily detectable amyloid assembly present in disease tissue, early work suggested that 
fibrils were likely to be the mediators of cell death and disease progression. In addition, 
preparation of stable mature amyloid fibrils has generally been more accessible than the 
potentially transient non-fibrillar oligomers, facilitating biophysical and structural analysis. 
With recent advances in methodology and instrumentation, high-resolution structural 
details have been reported for amyloid fibrils formed by several proteins and peptides, 
based on data from crystallographic and solid state (nuclear magnetic resonance) NMR 
studies (Petkova et al. 2002; Jaroniec et al. 2004; Sawaya et al. 2007; Lee et al. 2008; 2009). 
While the details of each structure differ, based on sequence and solution conditions used 
for assembly, these studies have confirmed the presence of a cross-β architecture within the 
core of all amyloid fibrils studied to date. This structural motif is characterized by having 
protein or peptide strands form extended β-sheets running perpendicular to the long axis of 
the filament, and was initially identified from x-ray fiber diffraction studies of amyloid 
fibrils (Eanes and Glenner 1968; Geddes et al. 1968; Jahn et al. 2009). The cross-β diffraction 
pattern contains intense reflections at 4.7-4.8 Å (meridional) and 10 Å (equatorial) due to the 
characteristic spacing between β-strands along the long axis and between the 
perpendicularly stacked β-sheets, respectively. 
In general, the core of most amyloid fibrils is considered to contain a dehydrated interface 
between adjacent β-sheets. This is typically considered to result from packing of 
hydrophobic residues in a water-excluded core, giving rise to one of 8 possible steric zipper 
arrangements, as first proposed by Sawaya et al. (Sawaya et al. 2007) (Figure 1A). These 
permutations arise from the fact that there are 2 possible types of β-sheet (parallel or 
antiparallel), 2 stacking possibilities (parallel or anti-parallel) and 2 surfaces for inter-sheet 
packing (face-to-face or face-to-back). The presence of steric zipper motifs was initially 
observed in X-ray structures of fibril-like crystals formed by short amyloidogenic peptides 
(Sawaya et al. 2007), and a subset of these classes of intersheet packing have been observed 
in solid-state NMR structures of amyloid fibrils (Nielsen et al. 2009). It is important to note, 
however, that recent NMR studies have revealed some possible structural differences 
between the crystalline and fibrillar forms of the GNNQQNY peptide derived from the 
yeast prion Sup35 (van der Wel et al. 2007), such that more structures of amyloid fibrils are 
required to confirm the crystallographic data.  
Additional complexity in fibril structure comes from quaternary interactions in which 
protofilaments containing a basic building block (for example a filament formed by 
extended arrangement of a pair of stacked β-sheets) are bundled or twisted together to form 
the mature amyloid fibril. It is clear from electron microscopy studies of fibrils formed by 
numerous amyloid peptides that significant heterogeneity can exist between fibrils formed 
by the same peptide (Fandrich et al. 2009). This can be rationalized as variations in the 
interchain, intersheet, and interprotofilament packing, as well as conformational 
heterogeneity between peptide chains. The heterogeneous nature of many fibril 
preparations has been supported by solid state NMR for Aβ(1-40) (Petkova et al. 2005), α-
synuclein (Heise et al. 2005), GNQQNY fibrils (van der Wel et al.), and amylin (Madine et al. 
2008). 
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Fig. 1. Stuctural models for amyloid fibrils. (A) Possible arrangements of beta-strands in an 
amyloid fibril. Eight permutations exist, four containing parallel β-sheets and four containing 
anti-parallel β-sheets, each with the possibility of parallel or antiparallel stacking of the two 
sheets, which may align in a face-to-face or face-to-back manner. In each case, the interface 
between the sheets forms a so-called steric zipper, with opposing side chains interdigitating 
to exclude water. Reprinted with permission from Nielsen et al., 2009. Copyright 2009 
Angewandte Chimie. (B) Structural model for Aβ(1-40) fibrils, as determined by solid state 
NMR. This structure contains a class 1 steric zipper with parallel β-sheets stacked in a face-
to-face antiparallel arrangement. The upper image shows the backbone of several 
monomers, arranged with the fibril axis extending into the page, while the lower image 
focuses on a representative pair of peptides, showing the interdigitation of sidechains within 
the hydrophobic core, as well as depicting quaternary contacts between adjacent 
protofilaments. Reprinted with permission from Petkova et al., 2002. Copyright 2002 
Proceedings of the National Acadamy of Science of the United States. (C) Structural model 
for amyloid fibrils formed by PrP(106-126), determined using solid state NMR. The peptide 
strands are arranged in a class 1 steric zipper motif with a salt bridge between K110 and the 
carboxylate of the C-terminus. The overall structural effect is similar to a single layer of the 
Aβ structure. Reprinted with permission from Walsh et al., 2009. Copyright 2009 Structure 
www.intechopen.com
 Advanced Understanding of Neurodegenerative Diseases 
 
92 
Probably the best characterized fibril structures are those formed by fragments of the 
Alzheimer’s Aβ protein. In particular, several structures for fibrils formed by Aβ(1-40) have 
been reported, based primarily on solid state NMR or transmission electron microscopy 
(TEM) (Chan 2011; Tycko 2011; Petkova et al. 2002; Sachse et al. 2008). The fibril morphology 
and subunit peptide structure in each case is dependent on the incubation conditions during 
in vitro fibrillization, and can exhibit significant heterogeneity in both TEM and NMR 
experiments. An example structure for Aβ(1-40) fibrils is shown in Figure 1B. Each peptide 
adopts a β-turn-β conformation, forming parallel in-register β-sheets with neighboring 
peptides down the long axis of the fibril. The two sheets pack into an internal class 1 steric 
zipper motif within the protofilament. In this structural model, quaternary interactions 
between two protofilaments were determined using intermolecular dipolar couplings from 
solid state NMR, giving rise to the depicted structure for the mature fibril. These quaternary 
interactions vary between fibrils with different morphology, such as the three-fold 
symmetric fibrils reported by Paravastu et al., (Paravastu et al. 2006) or those studied by 
cryoelectron microscopy (Sachse et al. 2008; Schmidt et al. 2009). 
By contrast, only a single well-defined structure has been reported so far for protofilaments 
formed by the far more neurotoxic and more aggregative Aβ(1-42) peptide, which is a less 
abundant form of Aβ, but which correlated more closely with pathogenesis (Burdick et al. 
1992; Jarrett et al. 1993; Luhrs et al. 2005; Kumar-Singh et al. 2006). This structure is similar 
to that of Aβ(1-40), but rather than intramolecular contacts forming the steric zipper, the top 
strand from one monomer makes side chain contacts with the bottom strand from an 
adjacent monomer. Modeling of the mature fibril based on cryoelectron microscopy and 
hydrogen/deuterium exchange measurements has suggested a distinctly different 
quaternary assembly for Aβ(1-42) fibrils, but the potential relationship between these 
structures and the varied biological activity of the two Aβ peptides remains (Miller et al.; 
Olofsson et al. 2007; Zhang et al. 2009). 
Numerous solid state NMR structures of small amyloid-forming peptides have now been 
reported, including short fragments of Aβ (Balbach et al. 2000; Tycko and Ishii 2003), amylin 
(Luca et al. 2007; Madine et al. 2008), transthyretin (Jaroniec et al. 2002; Jaroniec et al. 2004), 
calcitonin (Naito et al. 2004) and neurotoxic fragments of PrP (Cheng et al. 2011; Lee et al. 
2008; 2009). As shown for PrP(106-126) fibrils in Figure 1C, most of these structures reflect 
similar architecture as observed for Aβ, parallel β-sheets and a class 1 steric zipper packing. 
Some short peptides display alternate packing arrangements in the fibrils, such as the 
antiparallel β-sheets formed by Aβ(16-22) (Balbach et al. 2000) or the antiparallel 
heterozipper arrangement of amylin(20-29) fibrils (Nielsen et al. 2009). Longer amyloid 
proteins have remained more challenging. For example, initial studies of full-length α-
synuclein by hydrogen—deuterium exchange and solid state NMR have allowed 
identification of secondary structure elements and delineation of the fibril core, but a high-
resolution fibril structure is lacking (Heise et al. 2005; Vilar et al. 2008). 
2.2 Prion fibrils 
The prion protein (PrP) is the major causative agent of neurodegenerative prion diseases, 
such as scrapie in sheep, BSE in cattle, and CJD among others in humans. The protein 
converts from a monomeric, primarily helical cellular form (PrPC), to an infectious, 
oligomeric, scrapie form (PrPSc), with increased β-structure. In addition, there are several 
known fungal prion proteins, unrelated to PrP in amino acid sequence, but sharing the 
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ability to adopt a fibrillar, infectious, β-sheet rich structure. While sharing some common 
structural elements with fibrils formed by amyloid proteins, some striking differences have 
been observed. For example, the fungal Het-S prion protein structure solved by solid state 
NMR contains a β-solenoid structure with two protein molecules per “rung” of the solenoid 
ladder, rather than the cross-β packing typical of amyloid (Figure 2) (Wasmer et al. 2008). By 
contrast, amyloid fibrils formed by PrP in vitro were shown by electron paramagnetic 
resonance (EPR) to contain amyloid-like in-register parallel beta-sheet structure (Cobb et al. 
2007) (Figure 2), similar to the yeast prion proteins Ure2 (Baxa et al. 2007) and Sup35 
(Shewmaker et al. 2006). Interestingly, it has been shown through electron crystallography, 
X-ray fibre diffraction, and molecular dynamics simulations that the infectious PrPSc form of 
PrP from infected brains likely differs from in vitro fibrils and may contain a β-helix or β-
solenoid structure (Govaerts et al. 2004), similar to Het-S. 
 
 
Fig. 2. Structures formed by prion proteins from human and yeast systems. (A) Structure of 
amyloid fibrils formed by PrP, showing parallel in-register β-sheets. The structure is also 
stabilized by a disulphide bond. Reprinted with permission from Cobb et al., 2007. Copyright 
2007 Proceedings of the National Acadamy of Science of the United States. (B) β-helical 
structure formed by human PrP taken from infectious material. Reprinted with permission 
from Govaerts et al., 2004. Copyright 2004 Proceedings of the National Acadamy of Science 
of the United States. (C) The Het-S prion structure from solid state NMR showing residues 
218-289 in a β-solenoid. Reprinted with permission from Wasmer et al., 2008. Copyright 2008 
Science 
3. Non-fibrillar amyloid oligomers 
3.1 Overview 
While a wealth of structural information is becoming available for the fibrillar forms of 
many model and disease related amyloid proteins and peptides, relatively little is known 
about the molecular structure of non-fibrillar oligomers formed by the same polypeptides. 
Structural characterization has been made particularly challenging by the transient nature of 
many of these assemblies, which are widely considered to form as intermediates along the 
amyloid misfolding pathway. Thus, the difficulty of obtaining highly pure samples of non-
fibrillar oligomers which are sufficiently long-lived for biophysical studies has significantly 
slowed progress in this field. A number of studies have used small molecules, including 
detergents or lipids, to trap or stabilize oligomeric states of amyloid proteins (Laurents et al. 
2005; Yu et al. 2009), but this approach risks formation of off-pathway or non-productive 
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assemblies, rather than the on-pathway intermediates likely to play a role in amyloid 
disease (Kayed et al. 2003).  
Despite these challenges, however, a number of low-resolution studies have been reported, 
using TEM, atomic force microscopy (AFM), hydrogen/deuterium exchange, and 
fluorescence spectroscopy-based approaches (Huang et al. 2000; Williams et al. 2005; Losic et 
al. 2006; Ono et al. 2009). Microscopy and size exclusion chromatography have shown that, 
similar to amyloid fibrils, there are a wide range of non-fibrillar oligomers that can be 
categorized based on their size (ranging from dimers of Aβ(1-40) to large globular 
assemblies containing hundreds of peptide monomers) or morphology (Haass and Selkoe 
2007; Walsh and Selkoe 2007). In terms of the latter, most oligomers reported have either 
exhibited a roughly globular appearance by AFM and TEM, or have been annular in nature 
– exhibiting a pore or ring shaped structure (Janson et al. 1999; Conway et al. 2000; Lashuel 
et al. 2002). These two morphologies appear to exhibit different degrees of biological 
activity, with spherical oligomers, but not annular oligomers, increasing membrane 
conductance and inducing apoptosis in cell culture (Kayed et al. 2009). The large (3-10 nm 
diameter), spherical oligomers formed by several amyloid proteins have been shown to bind 
to a single conformational antibody, suggesting that a common structural motif exists in 
these assemblies, despite having no sequence similarity. Antibody binding was also shown 
to inhibit the inherent cytotoxicity of these large amyloid oligomers (Figure 3). Likewise, 
annular oligomers formed by Aβ(1-42), amylin and α-synuclein are all recognized by an 
antibody that does not bind to monomeric or fibrillar material, and that shows only weak 
binding to spherical oligomers, indicating that these contain distinct structural elements 
from the other assemblies (Kayed et al. 2009). 
More recently, solid state NMR has been successfully used to obtain high-resolution 
structural details of non-fibrillar oligomers formed by Aβ (Chimon and Ishii 2005; Chimon 
et al. 2007), PrP(106-126) (Walsh et al. 2009; Walsh et al. 2010), and α-synuclein (Kim et al. 
2009), and solution NMR has been used to investigate the structure of small detergent 
stabilized oligomers of Aβ(1-42) (Yu et al. 2009). Advances in computational infrastructure 
and methodologies have also led to an increased use of molecular dynamics simulations to 
investigate the structure and assembly of non-fibrillar amyloid oligomers. 
3.2 Aβ oligomers 
The non-fibrillar oligomers formed by Aβ(1-40) and Aβ(1-42) have been implicated as the 
main toxic species associated with Alzheimer’s disease, and as such have been the focus of 
the majority of studies on amyloid oligomers reported to date. Structural characterization 
has been impeded by the wide spectrum of oligomeric states that can be adopted by these 
peptides along their aggregation pathways. As indicated above, species ranging in size from 
dimers to oligomers containing hundreds of peptides have been reported, both in vitro, and 
in material isolated from the brains of Alzheimer’s patients (Haass and Selkoe 2007; Walsh 
and Selkoe 2007).  
The larger oligomers can also be subdivided into spherical, so-called pre-fibrillar oligomers 
and ring-shaped annular oligomers, each with different antibody reactivity. From a high-
resolution standpoint, most experimental progress has been made in defining the molecular 
structures of small and large pre-fibrillar oligomers formed by Aβ, although numerous 
molecular dynamics simulations have been carried out on membrane-bound amyloid 
channels or pores that closely resemble the overall morphology of annular protofibrils as  
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Fig. 3. Amyloid oligomers are toxic and share a common structural element. A graph 
showing the viability of neuroblastoma SH-SY5Y cells, monitored by the 3-(4,5-dimethyl-2-
thiazoyl)-2,5-diphenyltetrasodium bromide (MTT) reduction assay, as a function of 
treatment with preparations of several amyloid proteins. The toxicity of non-fibrillar 
oligomers formed by each peptide is shown to significantly decrease cell survival (black 
bars) relative to the control, soluble (presumed monomeric) peptide and mature amyloid 
fibrils. In each case, the effects of the oligomers on cell survival are attenuated by the 
addition of an amyloid oligomer specific antibody (A11, white bars). Non-specific IgG is 
shown in hatched bars, and exerts no effect on the system. Reprinted with permission from 
Kayed et al., 2003. Copyright 2003 Science 
seen in TEM and AFM images (Jang et al. 2007; Zheng et al. 2008). These annular oligomers 
are 8-20 nm in diameter by TEM and AFM, and like the spherical oligomers, circular 
dichroism (CD) spectroscopy shows that they contain high levels of β-sheet (Kayed et al. 
2008). The anti-annular oligomer antibodies also bind to the β-barrel pores formed by the 
bacterial toxin α-hemolysin, such that they may share the same general architecture (Kayed 
et al. 2009). Interestingly, preformed annular oligomers did not permeabilize membranes, 
instead converting to prefibrillar oligomers upon interaction with membranes. This may 
suggest that any pore like structure formed by Aβ would need to assemble within the 
membrane, rather than acting through insertion of a preformed assembly. 
In the pre-fibrillar oligomers, the structural data that has emerged from recent studies 
suggests that even at the earliest stages of aggregation they share common features with the 
fibrillar forms of Aβ. For example, Yu et al., used 0.05% SDS to stabilize very small pre-
globulomers and globulomers of Aβ(1-42), with molecular weights of 16 and 64 kDa 
respectively (Yu et al. 2009). These were assumed to represent very early points in the 
amyloid aggregation pathway, and structural studies were conducted using solution NMR.  
www.intechopen.com
 Advanced Understanding of Neurodegenerative Diseases 
 
96 
 
Fig. 4. Structures of non-fibrillar amyloid oligomers. (A) Pre-globulomer(top) and 
globulomer (bottom) structures formed by Aβ(1-42) are shown. Both structures show 
similarities to the basic Aβ(1-40) fibril subunit shown in Figure 1B. Reprinted with 
permission from Yu et al., 2009. Copyright 2009 The American Chemical Society. (B) 
Structural model of large spherical Aβ(1-40) oligomers obtained using solid state NMR. 
Reprinted with permission from Chimon et al., 2008. Copyright 2008 Nature Publishing 
Group. (C) A structural model of large, DSS stabilized Aβ(1-40) oligomers shown as 
extended micelle-like structures, approximately 35nm in diameter. Significant structural 
similarity with the solid state NMR derived model shown in (B) is evident. Reprinted with 
permission from Laurents et al., 2005. Copyright 2005 Journal of Biological Chemistry. (D) A 
structural model for non-fibrillar PrP(106-126) oligomers, obtained from solid state NMR, 
showing similar contacts to those seen in fibrils formed by the same peptide (Figure 1C). 
The basic subunit is a parallel beta sheet stacked two high to form a class 1 steric zipper 
which are arranged in a micelle-like formation. Reprinted with permission from Walsh et al., 
2010. Copyright 2010 The American Chemical Society 
The intra-chain and inter-chain contacts in these oligomers are share similarities with the Aβ 
(1-40) and Aβ(1-42) fibril structures reported to date. Both contain similar secondary 
structure elements with the fibrillar form, and contain intermolecular contacts reminiscent 
of the fibrils, although in the small oligomers, the N-terminal strand folds back on itself, 
rather than participating in intermolecular β-sheet formation (Figure 4A). In a similar vein, 
DSS was used to stabilize very large (764 kDa) Aβ(1-40) oligomers, and subsequent 
structural analysis suggested the presence of micelle-like assemblies containing a radial 
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arrangement of Aβ monomers in an extended β-sheet conformation (Figure 4C) (Laurents et 
al. 2005). The nature of intermolecular or intramolecular β-sheets was not determined in this 
study, so it is difficult to relate the resulting models to the fibrillar form of the protein. 
For both of the aforementioned studies, it is important to note that the effect of detergents 
and other small molecules on the structure and assembly of amyloid peptides remains 
unclear. Addition of cofactors may lead to formation or stabilization of otherwise 
unpopulated structures. Recent studies of on-pathway prefibrillar oligomers of Aβ(1-40) and 
Aβ(1-42) have circumvented this requirement by using either gel filtration and 
lyophilization (Chimon and Ishii 2005; Chimon et al. 2007) or careful modulation of solution 
salt and pH conditions to trap non-fibrillar oligomers for structural studies (Ahmed et al. 
2010).  
Solid state NMR of large (15-35nm) spherical oligomers of Aβ(1-40) prepared by freeze-
trapping revealed fibril-like secondary and quaternary structures, leading to a model in 
which the location and intermolecular assembly of β-sheets is shared between the two forms 
(Chimon et al. 2007). A schematic for the proposed architecture of these oligomers is shown 
in Figure 4B, along with a model of the Aβ(1-40) protofilament structure determined by 
Petkova et al. (Petkova et al. 2002). This micelle-like arrangement is reminiscent of that 
proposed for DSS-stabilized oligomers (Figure 4C), potentially validating the use of small 
molecules to trap transient amyloid oligomers. These large oligomers were shown to exhibit 
neurotoxicity, and based on their transient nature can be assumed to lie on the fibril 
assembly pathway. 
Ahmed et al. have used altered solution conditions to trap discoidal pentamers and 
decamers of Aβ(1-42) with potent neurotoxicity (Ahmed et al. 2010). When incubated at 
37°C for several hours, these oligomers convert to amyloid fibrils, suggesting that they are 
productive intermediates on the assembly pathway. In contrast to the large Aβ(1-40) 
oligomers studies by Chimon et al. (2007), Fourier-transform infrared (FTIR) spectroscopy 
and solid-state NMR studies of these small oligomers indicated the presence of significantly 
increased disorder and solvent accessibility relative to fibrils of Aβ(1-42), and showed that 
the oligomers lack the in-register parallel β-sheet architecture of the fibrillar form. The 
oligomeric peptides do, however contain the same β-loop-β secondary and tertiary fold 
observed in Aβ(1-42) and Aβ(1-40) fibrils. This is supported by molecular dynamics and 
hydrogen-deuterium exchange studies from several other groups, and leads to an overall 
picture in which Aβ peptides adopt a β-loop-β structure as a common element of all 
oligomeric states, with intermolecular contacts and solvent accessibility varying between 
different types of oligomers. MD and H/D exchange studies support these conclusions, 
leading to the general concept that early intermediates formed during Aβ assembly may be 
more solvent accessible and potentially more labile, and that conformational flexibility is 
likely to play an important role in their biological activity (Pan et al. 2011; Yu et al. 2010; Yu 
and Zheng 2011; Cheon et al. 2007; Zhang et al. 2009). 
3.3 PrP(106-126) oligomers 
The PrP derived peptide PrP(106-126) poses an interesting structure-toxicity relationship. 
Evidence has been presented both in favour of, and against, a dependence of PrP(106-126) 
toxicity on expression of cell-surface full length PrP (Brown 1998). However, it has also been 
shown that this PrP derived peptide is able to form both amyloid fibrils and cytotoxic 
oligomers, making it a useful model for studying the structural and mechanistic details of 
non-fibrillar amyloid oligomers (Forloni et al. 1993; Selvaggini et al. 1993; Jobling et al. 1999; 
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Salmona et al. 1999). For example, in studies by Kayed et al., non-fibrillar oligomers of 
PrP(106-126) were shown to form large (10-20nm diameter) spherical oligomers with similar 
morphology to Aβ, amylin, and several other amyloid proteins (Kayed et al. 2003). These 
oligomers cause increase membrane conductance and were cytotoxic to neuronal cell 
cultures, and have also been shown to disrupt model-membranes in a concentration 
dependent manner, as revealed by a liposome dye-release assay (Kayed et al. 2004; Walsh et 
al. 2009). Utilizing solid state NMR, a structural model was developed for these non-fibrillar 
oligomers (Figure 4D) (Walsh et al. 2010). Similar to the Aβ(1-40) oligomers reported by Ishii 
et al. (Chimon et al. 2007), large PrP(106-126) oligomers contain fibril-like secondary 
structure and intermolecular contacts, suggesting that they are composed of small fibril-like 
segments arranged in a micelle-like assembly. This is an interesting observation considering 
that these oligomers do not bind thioflavin-T, unlike the amyloid fibrils formed by PrP(106-
126), implying that the oligomers either lack the extended cross-β structure required for dye-
binding, or that the binding site for the dye is occluded in the oligomer structure.  
3.4 α-synuclein oligomers 
In the case of α-synuclein, despite its innate lipid binding ability, it is the aggregated state 
that is considered to gain cytotoxic function, likely acting through membrane 
permeabilization (Haass and Selkoe 2007). Strong evidence has been presented to suggest 
that oligomers lying on misfolding pathway leading to amyloid fibril formation are the 
most cytotoxic species formed by this protein (Lashuel et al. 2002). These oligomers were 
found to share common structural elements with other amyloid oligomers as seen by A11 
antibody binding (Kayed et al. 2007), and the presence of extensive β-sheet secondary 
structure in baicalin stabilized oligomers has been confirmed through FTIR and CD 
spectroscopy (Zhu et al. 2004; Hong et al. 2008). A recent study combined biophysical 
analysis with solution and solid state NMR to more closely investigate the structure and 
membrane interaction of non-fibrillar α-synuclein oligomers (Kim et al. 2009). Through solid 
state NMR it was shown that the pore forming contained β-sheet secondary structure but 
that there were significant differences between the structures of the monomeric, oligomeric 
and fibrillar states of this protein – contrasting with the studies of Aβ and PrP(106-126) 
oligomers referenced above.  
3.5 Other amyloid oligomers and common structural elements 
While several other amyloid proteins and peptides, including amylin and polyglutamine, 
have been shown to form neurotoxic, non-fibrillar oligomers, there is currently no high-
resolution structural information available on these systems. It is known that at least one 
oligomeric state populated by each peptide is morphologically similar to that observed for 
spherical aggregates of Aβ, PrP(106-126), and α-synuclein. These oligomers also cause 
increased membrane permeability (Kayed et al. 2004; Demuro et al. 2005), and furthermore 
share the common structural element that allows recognition by the A11 anti-oligomer 
antibody developed by Kayed et al. (Kayed et al. 2003). 
In the case of the mammalian prion protein, non-fibrillar oligomers of various sizes have 
been identified and shown to be neurotoxic (Baskakov et al. 2002; Sokolowski et al. 2003; 
Silveira et al. 2005; Simoneau et al. 2007). Small oligomers (composed of < 30 monomers) of 
PrP purified from the brains of infected animals have been shown to be the most infectious 
and toxic form of the protein, echoing the biological activity of amyloid oligomers (Silveira  
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et al. 2005). PrP oligomers have been shown to contain a predominantly β-sheet secondary 
structure by FTIR spectroscopy and CD, but no detailed structural information has been 
reported (Baskakov et al. 2001; Sokolowski et al. 2003). Of particular interest, the population 
of a β-sheet rich octamer formed during the misfolding of PrP has been shown to correlate 
with the susceptibility of different mammals to prion disease, further highlighting the role 
of oligomeric species in pathogenesis (Khan et al. 2010). 
3.6 Where do non-fibrillar oligomers fit into the misfolding pathways of amyloid 
proteins? 
The relationship between the formation of non-fibrillar oligomers and the misfolding 
pathway leading to amyloid fibril formation has not been definitively determined. While 
there have been conflicting reports (Necula et al. 2007), most evidence points to the 
spherical, cytotoxic oligomers existing as on-pathway intermediates. In particular, various 
prefibrillar oligomers of Aβ have been shown to be transient, disappearing as they 
reorganize into mature fibrils (Chimon and Ishii 2005). Similarly, pore forming oligomers of 
α-synuclein are considered to be on-pathway for fibrillization (Kim et al. 2009). From a 
mechanistic standpoint, the structural data on prefibrillar oligomers suggests early adoption 
of an extended β-structure, followed by formation of tertiary and quaternary contacts as the 
oligomers increase in size. The precise steps involved in the transition from discoidal or 
spherical oligomers to an extended amyloid fibril have not been determined, but likely 
involve an increase in the tightness of lateral associations between strands, with optimized 
hydrophobic packing and hydrogen bond formation driving the final steps of assembly. 
Taken together, the transient nature and fibril-like structure show that these entities exist on 
the aggregation pathway toward fibril. As described above, annular oligomers do not 
appear to exist as productive intermediates, but may instead represent off-pathway 
assembly. In the case of Aβ, it has been shown that in the presence of lipid membranes, 
prefibrillar oligomers are capable of rearranging to form annular oligomers, suggesting that 
in this case they may represent an alternate end-stage of the misfolding pathway (Kayed et 
al. 2009). This may also present a possible mechanism for formation of membrane-
disrupting entities from the on-pathway non fibrillar oligomers, as discussed below. 
4. Non-fibrillar amyloid oligomers as the cytotoxic agents in amyloid disease 
While early studies focused on the amyloid fibrils or plaques as the causative agents of 
neurotoxicity in Alzheimer’s disease, more recently it has become evident that small non-
fibrillar oligomers correlate much more closely with loss of neuronal function and 
neurodegenerative disease progression (Kayed et al. 2003; Haass and Selkoe 2007; Walsh 
and Selkoe 2007). This finding has been echoed for non-fibrillar oligomers formed by a 
broad array of disease related and non-disease related amyloid proteins (Baglioni et al. 
2006). Given the potential for some amyloid oligomers to have similar structural properties, 
regardless of amino acid sequence, it is possible that many of these may act via a similar 
toxic mechanism. The conformations accessible to aggregative proteins may create 
interactions with components of the cellular ion transport system or may allow them to form 
channels or pores in cell membranes (Lin et al. 2001; Kayed et al. 2004; Demuro et al. 2005). 
This may represent a general mechanism through which cytotoxic effects are exerted during 
the early stages of protein aggregation. Supporting this hypothesis, soluble amyloid 
oligomers with spherical morphology, induce vesicle leakage, and are toxic to cultured cells, 
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possibly through disruption of calcium homeostasis (Thellung et al. 2000; Demuro et al. 
2005; Ferreiro et al. 2008). 
Alternatively, hydrophobic, misfolded proteins are likely to have a high propensity to 
associate with membranes, and membrane binding of many amyloid peptides has been 
described extensively (McLaurin and Chakrabartty 1996; Yip et al. 2002; Kayed et al. 2004). 
Once bound to the membrane surface, or inserted into the bilayer, non-fibrillar oligomers 
would have the potential to rearrange into channels, pores, or non-specific aggregates at the 
membrane surface. Any of these mechanisms are likely to cause membrane destabilization 
and cell death, and it has recently been demonstrated for Aβ oligomers that increased 
membrane conductance can occur in the absence of channel formation (Sokolov et al. 2006). 
Physical disruption such as the introduction of membrane defects, possibly through 
insertion of oligomers, or through membrane-catalyzed fibril formation, would also be 
sufficient to induce leakage of cell contents and ultimately lead to cell death (McLaurin and 
Chakrabartty 1997; Yip et al. 2002).  
While the oligomer fold is distinct from that of fibrils, as determined by differential 
antibody reactivity, a common theme emerging from structural studies of non-fibrillar 
amyloid oligomers is the presence of local fibril-like structure. While it does not speak to the 
actual mechanism through which toxicity is exerted, this observation may suggest that small 
fibril-like assemblies are the key element required for cytotoxicity. A similar phenomenon 
has been reported by Xue et al. (Xue et al. 2009), who demonstrated that fragmentation of 
mature amyloid fibrils formed by α-synuclein, β2-microglobulin and lysozyme leads to an 
increase in membrane disruption and cytotoxicity (Figure 5). Likewise amyloid fibrils 
formed by hexapeptides gained cytotoxicity towards primary neuronal cell culture after 
physical disruption (Pastor et al. 2008). In both studies, it is likely that the increase in active 
ends allows improved interactions with cellular targets – membranes or other cell surface 
molecules, where they are able to rearrange to form active, toxic entities. Oligomeric species, 
which are known to be more conformationally flexible and less stable than their fibrillar 
counterparts, may act through a similar mechanism, carrying active fibril-like segments to 
the site of toxic activity. 
4.1 Aβ toxicity 
As with molecular structure, the link between oligomerization of an amyloid protein and 
disease progression has been explored in detail for Aβ. Several lines of evidence support a 
role for oligomers as the toxic entity in Alzheimer’s patients. Anti-oligomer antibodies stain 
diffuse amyloid in human brains, showing that soluble oligomers with similar structural 
properties as those formed in vitro exist in vivo (Kayed et al. 2007). In addition, both injection 
of in vitro formed oligomers into brain tissue, and reinjection of small soluble Aβ oligomers 
isolated from diseased animals are able to induce loss of synaptic function and neuronal 
death (Walsh and Selkoe 2004; Cleary et al. 2005; Haass and Selkoe 2007; Walsh and Selkoe 
2007). This experiment has also been performed for non-disease causing amyloid proteins, 
supporting a role for other amyloid oligomers as in vivo cytotoxins (Baglioni et al. 2006). 
Aβ oligomer toxicity in vitro has been attributed to several distinct mechanisms, including 
but not limited to, membrane disruption and the direct formation of ion channels. Certainly 
there have been numerous reports of increased membrane conductance or leakage in the 
presence of Aβ oligomers ranging from small globulomers to large prefibrillar assemblies 
(Chimon and Ishii 2005; Yu et al. 2009), with some evidence presented to support formation 
of discrete ion channels of pores (Arispe 2004; Quist et al. 2005). A lot of attention has been 
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focused on the latter, and several molecular modeling studies have proposed models for the 
structure of a putative pore or channel – typically a picket-fence arrangement of monomers 
adopting the β-loop-β structure from the fibril structures (Jang et al. 2007). Alternatively, 
alteration of the mechanical properties of the membrane could lead to increased 
conductance as observed by Sokolov et al. (Sokolov et al. 2006), although the structural basis 
for this is unclear. 
Several very specific proposals for Aβ oligomer toxicity have been proposed as alternatives 
to membrane disruption. As a group these invoke interactions with specific cell-surface 
targets, with subsequent alteration of normal protein activity leading to loss of neuronal 
function and possibly to cell death (Verdier et al. 2004; Yankner and Lu 2009). While too 
numerous to describe in detail here, proposed interaction partners for Aβ have included the 
serpin-enzyme complex receptor (SEC-R) and the insulin receptor, both of which are capable 
of binding to monomeric Aβ, although the physiological effects are unclear (Verdier and 
Penke 2004). Fibrillar Aβ, on the other hand has been shown to bind a wide array of cell-
surface proteins, including the receptor for advanced glycation end products (RAGE) 
complex and the amyloid precursor protein (Verdier and Penke 2004), leading in some cases 
in increased radical formation and oxidative stress. Similarly, binding to the α-7 nicotinic 
receptor can mediate N-methyl-D-aspartate (NMDA) receptor activity, with broad effects on 
cellular metabolism (Snyder et al. 2005). Any or all of these effects may play a role in loss of 
synaptic function, leading to symptomatic Alzheimer’s disease. Other proposed interactions, 
such as dysregulation of calcium channels, may be confounded by membrane disruption 
effects, making them harder to confirm. 
Less is known about potential interactions of soluble oligomers with cell surface receptor 
molecules, although similar targets to the fibrillar material have been proposed. An intriguing 
possibility arises from recent reports that oligomeric Aβ binds to the unstructured N-terminus 
of cellular PrP, with initial reports suggesting that the toxic effects of small Aβ oligomers 
may be mediated by this interaction (Lauren et al. 2009). If true, such an association may 
lead to an alteration of the as yet unidentified signaling functions of PrP, or may allow PrP 
to act as carrier for internalization of oligomeric Aβ. In this model, once inside the cell, the 
prefibrillar oligomers would exert loss of function effects on internal cellular components 
through mechanisms not yet identified. While this observation may provide a tantalizing 
link between two neurodegenerative disorders, more work need to be done to confirm the 
specificity of the interaction, and to define the potential role played by PrP. 
It is important to note that since Aβ exists in vitro and in vivo as a continuum of different 
oligomeric states, none of which are particularly stable, it is difficult to distinguish biological 
effects induced by one specific type of non-fibrillar oligomer. Therefore, it is entirely feasible 
that Aβ has significantly different physiological effects when in different oligomeric forms. 
Thus, it is difficult to exclude any of the putative mechanisms for involvement of Aβ 
oligomers in progression of amyloid disease without further study. 
4.2 PrP(106-126) toxicity 
There have been conflicting reports on the toxicity of PrP(106-126) largely due to 
confounding effects of its ability to form amyloid oligomers as well as potentially playing a 
role in conversion of full-length PrP to the infectious PrPSc form (Gu et al. 2002). PrP(106-
126) has been shown to be toxic in a number of different ways. Reports initially 
characterized PrP(106-126) as requiring full-length PrP for toxicity in cerebral endothelial 
cells (Deli et al. 2000). There is also significant evidence for PrP-independent cytotoxicity, 
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Fig. 5. The relationship between amyloid fibril length and toxicity. As the concentration of 
small fragments increases, increased membrane disruption and cellular toxicity are 
observed. As the fragments become smaller, it is proposed that they will be increasingly 
toxic to the cell. Reprinted with permission from Xue et al., 2009. Copyright 2009 The 
American Chemical Society 
but it is important to note that in most studies of PrP(106-126), the aggregation state of the 
peptide was not clearly defined, so the activity of prefibrillar oligomers is implicit rather 
than explicit in the results. PrP(106-126) has been shown to interact with L-type voltage 
sensitive calcium channels, causing apoptosis (Florio et al. 1998; Silei et al. 1999; Thellung et 
al. 2000). It has also been demonstrated that this peptide causes the activation of the JNK-c-
Jun pathway, leading to apoptosis shortly after peptide treatment (Carimalo et al. 2005). 
There have been several reports of direct membrane destabilization by PrP(106-126), 
including the formation of ion channels (Lin et al. 1997), or alterations in membrane 
viscosity (Salmona et al. 1997). More recent work using well-defined prefibrillar oligomers 
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of PrP(106-126) have shown that it causes permeabilization of model membranes (Kayed et 
al. 2004; Walsh et al. 2009) and induces cytotoxicity in neuroblastoma cell cultures (Kayed et 
al. 2003). It is well known that PrP(106-126) interacts with phospholipid membranes even as 
a monomeric peptide, with lipid composition playing a role both in interaction and post-
binding events. For example, PrP(106-126) has been shown to cause the aggregation of 
liposomes containing the ganglioside GM1 (Kurganov et al. 2004). While there is no direct 
link to the disruption of calcium channels or activation of the JNK-c-jun pathway, current 
evidence supports direct membrane interaction and disruption as a mechanism for PrP(106-
126) cytotoxicity – at least in the absence of cell surface PrP. While unlikely in the face of 
recent studies for Aβ oligomers that show that structural alterations of the membrane are 
sufficient to increase conductance without requiring channels, rearrangement of the protein 
in the membrane to form discrete pores or channels cannot be ruled out (Eliezer 2006; 
Sokolov et al. 2006). 
In terms of the structure-function relationship of PrP(106-126) oligomers, the similarities 
between the peptide subunits within the oligomeric and fibrillar forms of this protein are 
reminiscent of the large oligomers of Aβ(1-40) described by Chimon et al. (Chimon et al. 
2007). Similar to one of the hypotheses proposed for Aβ, the insertion of small fibril 
fragments into the membrane may directly disrupt the membrane, nucleate the assembly of 
membrane-disruptive amyloid fibrils, or potentially rearrange into a toroidal or barrel stave 
type pore. In either case, the structural data supports the possibility of a common 
mechanism of action linking large spherical oligomers of Aβ and PrP(106-126). 
4.3 α-synuclein toxicity 
The toxicity associated with α-synuclein appears to be slightly different than other amyloid 
systems. To start with, α-synuclein is significantly larger (140 amino acids) than Aβ (40 or 42 
residues), amylin (37 residues), or many other amyloidogenic proteins. Additionally, in its 
native state α-synuclein is intrinsically disordered, gaining α-helical structure upon binding 
to phospholipid membranes (Weinreb et al. 1996; Eliezer et al. 2001; Ulmer et al. 2005). In 
Parkinson’s disease, α-synuclein forms β-sheet rich aggregates, culminating in the formation 
of amyloid fibrils (Lashuel et al. 2002; Lashuel et al. 2002). Not surprisingly, given its innate 
propensity to interact with membranes, the cytotoxic oligomers of α-synuclein have been 
shown to physically alter the conductance of planar bilayer membranes, presumably 
through the formation of pores (Kim et al. 2009). Multiple conductance levels were observed 
upon addition of these spherical, 15-30 nm diameter oligomers to lipid bilayers. The 
conductance profiles were similar to those observed for bee-venom mellitin, further 
supporting the formation of amyloid pores by these oligomers. Intriguingly, these pore-
forming α-synuclein oligomers were recognized by the A11 antibody, which is specific for 
prefibrillar oligomers, suggesting that there are some common structural features shared 
with other amyloid oligomers, and providing an additional argument in favor of direct 
membrane disruption by prefibrillar oligomers. 
5. Conclusion 
It is clear that despite significant advances in the past decade, the link between 
accumulation of amyloidogenic proteins as β-sheet rich oligomers and disease pathogenesis 
remains somewhat unclear. In particular, the mechanism or mechanisms through which 
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various non-fibrillar oligomers are capable of inducing cell death remain to be 
unambiguously determined. This is inextricably linked to questions of disease relevance – 
do all of the oligomers observed in vitro play a role in cell death during amyloidosis, and do 
they act through the same mechanisms? While the concept of a common mechanism of 
amyloid toxicity is attractive, given the broad range of cellular and tissue level effects 
reported to date, it may represent an oversimplification of a complex system. 
Certainly it is possible that despite some common structural motifs and a shared ability to 
physically disrupt membranes, different oligomeric species formed by different amyloid 
proteins may exert a range of activities, all leading to the same effective endpoint – cell 
death and degenerative disease progression. Additional questions surround the fibril-like 
structures observed in most toxic amyloid oligomers described to date. Does this relate to 
studies showing that fragmentation of amyloid fibrils can create cytotoxic, membrane 
disrupting species, or are these fibril fragments acting via distinct pathways from 
prefibrillar oligomers? Ongoing efforts in structure determination of oligomers formed by 
different amyloid proteins, and in defining the molecular mechanisms for their cytotoxicity, 
will be required in order to address these important questions and to elucidate the link 
between structure and toxic function. 
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